


BSE SENSEX
80,544

S&P CNX
24,574

CMP: INR80

TP: INR101 (+26%)

Buy



Stock Info

Bloomberg	NIVABUPA IN
Equity Shares (m)	1846
M.Cap.(INRb)/(USDb)	148.8 / 1.7
52-Week Range (INR)	109 / 61
1, 6, 12 Rel. Per (%)	-2/-5/-
12M Avg Val (INR M)	590

Financials Snapshot (INR b)

Y/E March	2025	2026E	2027E
NEP	48.9	61.4	79.6
U/W Profit	-2.5	-4.4	-2.6
PBT	2.1	1.8	4.4
PAT	2.1	1.1	3.3
EPS (INR/share)	1.2	0.6	1.8
EPS Growth (%)	142.7	-48.0	195.5

Ratios (%)

Claims	61.2	64.8	63.3
Commission	19.8	20.2	19.8
Expense	20.2	17.5	15.5
Combined	101.2	102.4	98.6
RoE	7.9	3.2	8.1

Valuations

P/E (x)	68.8	132.4	44.8
P/BV (x)	4.8	3.8	3.5

Shareholding pattern (%)

As On	Jun-25	Mar-25
Promoter	55.4	56.0
DII	15.1	9.7
FII	10.8	8.9
Others	18.8	25.4

FII includes depository receipts

Sharpening the moat

- We [initiated coverage on Niva Bupa](#) in Apr'25 highlighting the faster-than-industry growth momentum, product innovation capabilities, high standards of customer servicing and its focus on strengthening profitability. In its annual report, Niva Bupa has reiterated its strategic moat with product market fit, multi-channel scale, digital leverage and profitable growth.
- The five pillars of Niva's strategy include (1) being the health partner of choice for customers, (2) building a multichannel and diversified distribution with emphasis on digital sales, (3) technology and analytics-driven business model, (4) disciplined underwriting and claims management, and (5) talent management and execution.
- FY25 marked a defining year for Niva with the company going public. Niva delivered strong growth, profitability, and operating discipline. It continued to strengthen its leadership in the retail health space while improving operating ratios, launching segment-led products, and scaling up its partner and digital infrastructure.
- Niva Bupa's product portfolio now caters to all customer cohorts, with the launch of "Rise" for the underserved middle class. "ReAssure 2.0" and "Health Premia" reinforce retention at the upper end and "Aspire" takes care of younger individuals.
- A majority of new business continues to be sourced digitally, and the automation in policy issuance and claims is rising. With retail health making up 65.5% of its portfolio, an improving combined ratio, and strong solvency, the building blocks are in place for sustained profitable growth.
- **FY25 financial performance highlights:**
 - GWP grew 32.1% YoY (ex-1/n impact); reported GWP (IGAAP) grew 20.6% YoY to INR67.6b.
 - Combined ratio (ex-1/n) improved to 96.1%, despite a marginal increase in loss ratio, showcasing operational efficiency. Combined ratio (IGAAP) was at 101.2% and claims ratio increased to 61.2% due to a change in the portfolio mix and price corrections.
 - PAT grew 161% YoY to INR2.1b.
 - Solvency ratio stood at 3.03x, well above the minimum regulatory level.

Valuation: Niva Bupa continues to deepen its leadership in the retail health segment while improving profitability and strengthening its partner and digital stack. While short-term profitability metrics remain impacted by scale-up and regulatory changes, we believe the franchise is well-placed to deliver long-term profitable growth, supported by product innovation, digital leverage, and segment-specific distribution. We expect the company to report a CAGR of 29%/27%/24% in GWP/NEP/PAT over FY25-27 and the combined ratio to improve gradually to 98.6% in FY27. We value the stock at 40x FY27E IFRS PAT, arriving at a fair value of INR101. **Reiterate BUY.**

Research Analyst: Prayesh Jain (Prayesh.Jain@MotilalOswal.com) | **Nitin Aggarwal** (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Kartikeya Mohata (Kartikeya.Mohata@MotilalOswal.com) | **Muskan Chopra** (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

STORY IN CHARTS

Exhibit 1: GWP growth momentum remains strong




Exhibit 2: 1/n impact on GWP in FY25




Exhibit 3: GWP mix (%)




Exhibit 4: NEP trending upward




Exhibit 5: Based on health GWP, Niva beats industry growth




Exhibit 6: Based on GWP growth, Niva is ahead of SAHIs




Exhibit 7: Niva continues to gain market share in retail health




Exhibit 8: 1/n impacted combined ratio in FY25




Exhibit 9: Niva maintains healthy solvency ratio




Exhibit 10: Underwriting profitability trend




Exhibit 11: Investment book continues to grow




Exhibit 12: Trend in PAT




Exhibit 13: RoE witnessed improvement in FY25




Exhibit 14: IFRS PAT trend




Exhibit 15: IFRS claim ratio trend




Exhibit 16: IFRS combined ratio trend




Exhibit 17: Snapshot of key parameters

	FY23	FY24	FY25
GWP (INR b)	40.7	56.1	67.6
NWP (INR b)	31.8	44.2	53.7
PAT (I-GAAP) (INR m)	125.0	819.0	2,135.0
Combined Ratio	97.1%	98.8%	101.2%
AUM (INR b)	33.7	54.6	81.8
Investment yield	6.7%	7.1%	7.4%
RoE	1.9%	5.7%	8.4%
Retail health market share	8.4%	9.1%	9.4%
Average ticket size per policy (INR)	26,084	28,797	30,252
Claim settlement ratio	90.5%	91.9%	92.4%

Source: MOFSL, Company

Exhibit 18: Segment-wise performance – FY25

Parameters	Health	PA	Travel
GDPI growth	20%	38%	-11%
Net retention ratio	79%	84%	34%
Net commission ratio	19%	33%	88%
EoM to NWP ratio	49%	58%	141%
Claims ratio	62%	33%	126%
Combined ratio	101%	85%	261%

Source: MOFSL, Company

Industry-leading growth with market share accretion

- **Maintaining strong growth momentum:** Niva delivered a standout performance in FY25, with GWP growing 20.6% YoY to INR67.6b (32% YoY growth excluding 1/n impact). The company outperformed the health insurance industry, which reported 9% YoY growth in FY25.
- **Market share accretion:** Niva's retail health market share rose to 9.4% in FY25 from 9.1% in FY24, making Niva the third-largest standalone health insurer (SAHI). This consistent market share gain comes amid intensifying competition in the SAHI space and a larger shift toward bundled health offerings by general insurers and group products.


Product innovation – Key to increase market penetration

- Retail health continues to be the cornerstone of Niva's product portfolio, contributing 65.5% of GWP in FY25. This is complemented by 32.3% contribution by the group health segment and 2.2% contribution by PA & travel segments, reflecting a balanced portfolio.
- Niva is strategically positioned to seize the substantial opportunity in the under-penetrated retail health segment through the deepening of its product portfolio to meet diverse and evolving customer needs.
- Niva's product innovation strategy stands out in feature differentiation and its ability to unlock new addressable segments and deepen customer relationships. The company's product portfolio is tailored across age, health conditions, income segments and sales channels.
- The flagship ReAssure 2.0 with features like ReAssure Forever, Lock the Clock, and Booster+ continues to anchor the **affluent and urban salaried** segment. Meanwhile, offerings like Health Premia and Senior First cater to its niche yet expanding **HNI and elderly** customer base with a mix of international coverage, OPD limits, and two-hour hospitalization features. The Aspire product, designed for **Gen Z and Millennials**, incorporates maternity and surrogacy support (M-

iracle), cashback for claim-free years (Cash-bag), and even coverage for a future spouse under Future Ready.


- During FY25, Niva launched a new product “Rise,” which is highly affordable, making it attractive for underserved customers in the Tier III and Tier IV cities and rural areas. This product has features like Flexi Pay (flexible premium payment options including convenient monthly instalments) and Smart Cash (for immediate needs and attractive return benefits upon maturity or specific milestones). With this product, the company has presence in the **mass market** segment as well.

Exhibit 19: Balanced product mix with strong retail focus



Source: MOFSL, Company

Exhibit 20: Comprehensive product portfolio across all stages of customer lifecycle




Source: MOFSL, Company

Multi-channel approach – Focus on expanding reach


- Niva Bupa has built a diversified and scalable distribution model to enhance its reach and customer access across markets. The company operates through a multi-channel approach, combining traditional and digital channels, including agency, bancassurance, brokers, and direct online platforms. As of FY25, the company has established a nationwide footprint with 212 branches, 103 banks and corporate agency partners, and 540 active brokers, enabling presence across urban and semi-urban markets.
- The agency channel remains a key pillar, with a significant investment in pan-India expansion and huge retail proportion. Niva Bupa works with 180,000+ individual agents (+26% YoY), ensuring broad customer access and last-mile delivery. All new customers onboarded via the agency channel are digitally processed, reflecting full adoption of paperless, app-enabled enrollment. The channel witnessed premium growth of 12% YoY in FY25.
- The bancassurance channel is among the largest in the SAHI industry, delivering high growth and deep market penetration and witnessing premium growth of 24% YoY. Niva Bupa has partnered with leading institutions, including HDFC Bank, Axis Bank, Policybazaar, Bajaj Finserv, and Bank of Baroda. These alliances contribute significantly to premium growth and provide access to a wide customer base through bundled offerings and co-branded campaigns.
- Broker channel is the biggest contributor to the company's premiums, contributing 31% of GWP in FY25. ~0.7m policies were sold via broker channel with premium growth of 37% YoY.
- The company continues to strengthen its digital distribution capabilities with growing traction in direct online sales and digital intermediary partnerships. In FY25, 99.9% of new policies were applied via the website or mobile app, while 88.3% of renewals were completed without human intervention, and 91.5% of claims were submitted digitally. Tools like the UNO App and Digital Dukaan support intermediaries and agents in managing leads, completing policy sales, and accessing training content on the go.

Exhibit 21: Well diversified distribution mix



Source: MOFSL, Company

Exhibit 22: Strong growth in agent count in FY25




Source: MOFSL, Company

Enhanced customer experience backed by technology

- Niva continues to invest in internal capabilities, including technology, data analytics and talent development, to enhance agility and customer centricity. During FY25, multiple transformational advances resulted in end-to-end automation across customer onboarding, servicing, and claims processing, resulting in faster turnaround times and a superior customer experience. Even the traditionally offline agency channel onboards 100% of new customers digitally.
- Niva Bupa Health app provides a holistic customer health proposition. Customers can access digital consultations and second medical opinions directly through the app. It also enables home delivery of medicines, booking of diagnostic tests with home sample collection, and provides access to health education content on diseases published by Bupa. The app includes an activity tracker with step-based discounts on curated products, along with health assessment tools such as a BMI calculator and a stress calculator. Users also have access to a curated matrix on provider infrastructure and quality to support informed healthcare decisions.
- In FY25,
 - 99.9% of new policies were applied through the company's digital platforms,
 - 88.3% of renewals were completed without human intervention,
 - 91.5% of claims were submitted digitally,
 demonstrating high digital adoption among customers.
- In FY25, 49.5% of retail policies were auto-decided, and 28.5% of cashless claims were processed through auto-adjudication. These tools help reduce turnaround times, eliminate manual friction, and provide a smoother onboarding and claims experience. Automation has also improved the speed of pre-authorization decisions, reducing it from ~30 minutes to just a few minutes for eligible cashless claims.
- To enable hyper-personalized interactions, Niva Bupa has implemented real-time analytics across customer touchpoints. A predictive lapse model helps identify high-risk policies and proactively improve retention, while real-time lead scoring powers dynamic product recommendations. These insights also feed into LTV-based pricing and upsell/cross-sell opportunities, reinforcing customer engagement and stickiness.

Exhibit 23: Improving opex ratio on the back of enhanced tech capabilities



Source: MOFSL, Company

Robust claims management and provider network


- Niva's claim settlement has stayed above 90% for several consecutive years. Focus on quality business, fraud prevention and LTV-based predictive modelling helps protect margins while ensuring fair and timely claim settlements.
- As a result of focus on elevating customer experience, Niva witnessed significant improvement in claims NPS at the time of discharge from 63 in FY24 to 67 in FY25.
- The company received 1,028,339 claims in FY25 vs. 704,615 received in FY24, an increase of around 46% on account of health claims. Including the claims outstanding at the beginning of the year, the company settled 944,079 claims, thereby increasing the claims settlement ratio to 92.4% in FY25. The number of claims outstanding as on FY25-end stood at 21,861.
- For FY25, Niva's claims settled but not paid to policyholders for more than six months are nil.
- An important pillar of operational delivery is the company's pan-India hospital network, which grew to over 10,421 network hospitals in FY25. This extensive coverage provides access and affordability to customers. The preferred partner network is now active in 40 cities across India, covering 589 hospitals with benefits like free ambulance services, designated relationship manager and discounts on pharmacy, diagnostics and consultations even after discharge.

Exhibit 24: Aging of pending claims

Duration	As of 31st Mar'25				As of 31st Mar'24			
	Health	PA	Travel	Total	Health	PA	Travel	Total
Within 30 days	21,343	252	115	21,710	15,055	163	80	15,298
31 days - 6 months	131	20	-	151	72	6	-	78
>6 months - 1 year	-	-	-	-	-	-	-	-
> 1 year - 5 years	-	-	-	-	-	-	-	-
5 years and above	-	-	-	-	-	-	-	-
Total	21,474	272	115	21,861	15,127	169	80	15,376


Source: MOFSL, Company

Exhibit 25: Low average claim settlement time



Source: MOFSL, Company

Exhibit 26: 90%+ claim settlement ratio consistently



Source: MOFSL, Company

Proactive alignment with regulatory developments

IRDAI has continued to take significant steps to improve the accessibility and inclusivity of health insurance, with a particular focus on senior citizens.

- A key regulatory change mandates that all insurers must offer at least one product without any upper age limit, addressing the previous norm where most policies capped eligibility at 65 years. This reform ensures that senior citizens and individuals above the traditional age limit now have more coverage options.
- Series of customer-centric measures like a reduction in the waiting period for pre-existing diseases, mandatory coverage for high-risk individuals, customized plans for specialized groups, inclusion of AYUSH treatments without sub-limits and clear reimbursement guidelines for out-of-network services were also introduced.
- Regulatory sandbox framework underwent transformation to a more principle-based structure with greater flexibility and cross-sector collaboration. This shift is aimed at enhancing operational efficiency, encouraging experimentation, and improving ease of doing business.
- IRDAI has implemented stringent data governance requirements to strengthen privacy and security. Insurers are now required to adopt comprehensive data governance frameworks and maintain robust electronic records with high-level security protocols.
- The revised regulatory framework to recognize premiums and commissions for long-term policies over the duration of the policy rather than upfront at the time of issuance is expected to moderate GWP growth for the industry. However, this will help in alignment with global accounting standards and promote greater transparency and consistency in financial reporting.

Exhibit 27: Impact of 1/n accounting on profitability and growth of Niva Bupa

Key Ratios	FY24	FY25	Change
Operating Profit Ratio	4.93%	3.68%	-25%
Gross direct premium growth	37.68%	20.59%	-45%

Source: MOFSL, Company


- Going forward, the adoption of IFRS accounting standards, which align Indian insurance practices with global norms, will enhance transparency and comparability. The company is also actively preparing for the transition to risk-based capital frameworks, which will strengthen the industry's financial resilience and long-term sustainability.
- The proposed composite license framework will be a promising development enabling insurers to offer multiple lines of business under a single entity. This reform could be a game-changer, allowing greater participation from private players, improving operational efficiency, and expanding the overall insurance footprint.
- The 18% GST on health insurance premiums remains a key affordability challenge. With inflationary pressures mounting, a rationalization of GST rates could significantly improve penetration, especially among underserved and price-sensitive segments.

- The proposal to allow 100% FDI in the insurance sector could unlock new capital inflows, attract global players, and enhance competition, ultimately benefiting consumers through better products and services.

Combined ratio impacted by 1/n accounting in FY25

- Niva Bupa demonstrated improved operating efficiency in FY25, with key profitability ratios reflecting stronger underwriting performance and cost management.
- The company reported a loss ratio of 61.2% in FY25 (vs. 59% in FY24). The increase was owing to portfolio mix changes and pricing corrections.
- In FY25, Niva Bupa reported a combined ratio of 96.1% (excluding the impact of 1/n), an improvement from 96.9% in FY24, reflecting better cost management and operating efficiency, which was offset by an increase in the claims ratio. On an IGAAP basis, the combined ratio was at 101.2%.

Exhibit 28: Combined ratio at 101.2% for FY25



Source: MOFSL, Company

Outlook for the health insurance industry remains positive

- The Indian health insurance industry is at a pivotal juncture, poised for both significant market expansion and deeper market penetration. The growth momentum will be driven by progressive regulatory reforms, rising awareness and rising cost of healthcare.
- While premium hikes in FY25 impacted affordability, they have also heightened the realization of the importance of health insurance.
- There has been a rise in wellness-linked insurance products with increasing understanding for preventive care. Features like premium discounts for healthy lifestyles, health checkups, coverage for modern and AYUSH treatments will find their way into health insurance offerings.

Valuation and view

- Health insurance GWP has clocked a CAGR of 16% during FY19-25. Considering the demographically young country like India, rising disposable incomes and improving health awareness, this growth is sustainable and expected to accelerate further.
- However, in FY25, the industry growth rate was impacted by the implementation of 1/n accounting (from Oct'24).

- Niva Bupa maintained an industry-leading growth trajectory, with 20.6% YoY growth in GWP in FY25. Excluding the impact of 1/n, growth was strong at 32.1% YoY. This reflects Niva Bupa's strong positioning in the fast-growing retail health space, backed by a differentiated execution approach. The company's consistent growth, combined with improving underwriting and cost efficiencies, underpins its transition from scale to profitability. Its strategy of segment-specific product development, digital operating model, and partner diversification provides a solid foundation to sustain performance amid industry reforms.
- Niva Bupa continues to deepen its leadership in the retail health segment while improving profitability and strengthening its partner and digital stack. While short-term profitability metrics remain impacted by scale-up and regulatory changes, we believe the franchise is well placed to deliver long-term profitable growth, supported by product innovation, digital leverage, and segment-specific distribution. We expect the company to report a CAGR of 29%/27%/24% in GWP/NEP/PAT over FY25-27 and the combined ratio to improve gradually to 98.6% in FY27. We value the stock at 40x FY27E IFRS PAT, arriving at a fair value of INR101. **Reiterate BUY.**

Exhibit 29: IFRS Income Statement

INRm	FY23	FY24	FY25	FY26E	FY27E
Insurance Revenue	30,356	44,179	58,399	76,039	96,890
% YoY growth		46	32	30	27
Insurance Service Expense	-18,196	-27,785	-36,916	-49,031	-62,066
Deferred acquisition cost	-8,759	-13,012	-18,298	-22,812	-28,970
Net expenses from reinsurance	-713	-483	-615	-737	-939
Insurance service result	2,688	2,898	2,570	3,459	4,915
Investment income	1,893	3,081	4,759	6,422	7,252
Other income	70	37			
Other operating expenses	-4,187	-4,235	-4,347	-4,943	-5,523
Finance costs	-344	-352	-366	-352	-352
PBT	120	1,430	2,616	4,586	6,292
Tax	-35	-366	-731	-1214	-1666
PAT	85	1,064	1,885	3,372	4,626
RoE		6.8	7.4	9.7	12.0

Source: MOFSL, Company

Financials and valuation

Income Statement							(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
GDPI	12,429	17,508	28,100	40,730	56,076	67,622	86,506	1,12,618
Change (%)	31.2	40.9	60.5	44.9	37.7	20.6	27.9	30.2
NWP	9,537	13,485	21,576	31,831	44,209	53,694	69,029	90,094
NEP	8,411	11,509	17,525	26,628	38,113	48,945	61,377	79,561
Change (%)	27.5	36.8	52.3	51.9	43.1	28.4	25.4	29.6
Net claims	4,500	6,456	10,886	14,393	22,495	29,950	39,779	50,354
Net commission	429	635	1,204	1,908	7,482	10,646	13,925	17,839
Expenses	4,195	5,495	8,574	11,802	10,085	10,846	12,048	13,976
Underwriting Profit/(Loss)	-713	-1,077	-3,139	-1,476	-1,949	-2,498	-4,375	-2,607
Investment income (PH)	412	564	873	1,344	1,667	2,874	3,870	4,432
Operating profit	1,474	1,762	2,717	3,642	2,163	1,425	977	1,398
Investment income (SH)	1,173	1,249	451	3,509	1,880	1,801	471	3,222
Expenses	259	282	366	560	1,375	1,925	2,552	2,820
PBT	-616	-498	-1,965	125	818	2,135	1,773	4,371
Tax	-	-	-	-	-	-	663	1,093
PAT	-616	-498	-1,965	125	818	2,135	1,109	3,278

Balance sheet							(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
Equity Share Capital	11,260	13,497	14,086	15,107	16,995	18,270	18,270	18,270
Reserves & Surplus	-7,801	-7,730	-9,010	-6,796	3,502	12,338	20,607	23,885
Net Worth	3,459	5,767	5,076	8,311	20,498	30,608	38,877	42,155
FV change	2	0	-20	-31	9	-31	-	-
Borrowings	-	-	2,500	2,500	2,500	2,500	2,500	2,500
Other liabilities	8,912	13,224	22,328	30,485	41,412	67,024	64,762	81,304
Total Liabilities	12,373	18,991	27,384	38,766	61,919	97,602	1,03,639	1,23,459
Investments (SH)	4,029	6,374	8,696	11,555	25,855	36,199	36,356	40,919
Investments (PH)	6,643	9,842	15,317	22,107	28,728	45,552	51,424	57,878
Net Fixed Assets	412	475	497	556	588	753	803	853
Current Assets	1,100	1,996	2,286	3,530	5,320	12,895	8,218	10,699
Cash & Bank	189	304	588	1,019	1,428	2,204	6,839	13,111
Total Assets	12,373	18,991	27,384	38,766	61,919	97,602	1,03,639	1,23,459

E: MOFSL Estimates

Financials and valuation

Ratios

Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
GWP growth	31.2	40.9	60.5	44.9	37.7	20.6	27.9	30.2
NWP growth	30.4	41.4	60.0	47.5	38.9	21.5	28.6	30.5
NEP growth	27.5	36.8	52.3	51.9	43.1	28.4	25.4	29.6
Claim ratio	53.5	56.1	62.1	54.1	59.0	61.2	64.8	63.3
Commission ratio	4.5	4.7	5.6	6.0	16.9	19.8	20.2	19.8
Expense ratio	44.0	40.7	39.7	37.1	22.8	20.2	17.5	15.5
Combined ratio	102.0	101.6	107.4	97.1	98.8	101.2	102.4	98.6

Profitability Ratios (%)

RoE	-20.2	-10.8	-36.2	1.9	5.7	7.9	3.2	8.1
-----	-------	-------	-------	-----	-----	-----	-----	-----

Valuations	2020	2021	2022	2023	2024	2025	2026E	2027E
BVPS (INR)	3.1	4.3	3.6	5.5	12.1	16.8	21.3	23.1
Change (%)	14.8	39.1	-15.7	52.7	119.2	38.9	27.0	8.4
Price-BV (x)	26.2	18.8	22.3	14.6	6.7	4.8	3.8	3.5
EPS (INR)	-0.5	-0.4	-1.4	0.1	0.5	1.2	0.6	1.8
Change (%)	11.0	-32.5	277.9	-105.9	480.6	142.7	-48.0	195.5
Price-Earnings (x)	-147.0	-217.8	-57.6	969.3	166.9	68.8	132.4	44.8

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$< -10\%$ to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@grievances@motilaloswal.com.